Effects of controlled-release on the pharmacokinetics and absorption characteristics of a compound undergoing intestinal efflux in humans

European Journal of Pharmaceutical Sciences

Volumn 29, Issue 3-4 SPEC. ISS., 2006, Pages 231-239

  Tubic, Marija ^a   Wagner, Daniel ^a   Spahn Langguth, Hildegard ^a   Weiler, Christine ^a   Wanitschke, Roland ^a   Böcher, Wulf Otto ^a   Langguth, Peter ^a  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

Author keywords

Absorption; Controlled release; P glycoprotein; Pharmacokinetics; Sustained release; Talinolol

Indexed keywords

TALINOLOL;

ADULT; ARTICLE; BLOOD SAMPLING; CONTROLLED RELEASE FORMULATION; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG EXCRETION; DRUG HALF LIFE; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; INTESTINE ABSORPTION; MALE; NORMAL HUMAN; PRIORITY JOURNAL; TABLET; URINALYSIS; URINARY EXCRETION; VOLUNTEER;

ADULT; DELAYED-ACTION PREPARATIONS; FEMALE; HUMANS; INTESTINAL ABSORPTION; MALE; P-GLYCOPROTEIN; PROPANOLAMINES; SOLUBILITY; TABLETS;

EID: 33750184464     PISSN: 09280987     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejps.2006.04.005     Document Type: Article

References (34)

1. Ayrton A., and Morgan P. Role of transport proteins in drug absorption, distribution and excretion. Xenobiotica 31 (2001) 469-497
2. Bogman K., Zysset Y., Degen L., Hopfgartner G., Gutmann H., Alsenz J., and Drewe J. P-glycoprotein and surfactants: effect on intestinal talinolol absorption. Clin. Pharmacol. Ther. 77 (2005) 24-32
3. Brady J.M., Cherrington N.J., Hartley D.P., Buist S.C., Li N., and Klaassen C.D. Tissue distribution and chemical induction of multiple drug resistance genes in rats. Drug. Metab. Dispos. 30 (2002) 838-844
4. Deferme S., Tack J., Lammert F., and Augustijns P. P-glycoprotein attenuating effect of human intestinal fluid. Pharm. Res. 20 (2003) 900-903
5. Garg D.C., Weidler D.J., and Eshelman F.N. Ranitidine bioavailability and kinetics in normal male subjects. Clin. Pharmacol. Ther. 33 (1983) 445-452
6. Gibaldi M., and Perrier D. Pharmacokinetics (1982), Marcel Dekker, New York
7. Giessmann, T., Zschiesche, M., Modess, C., Tschuschke, A., Hartmann, V., Wegner, D., Weitschies, W., Siegmund, W., 2001. Is the double peak phenomenon of talinolol caused by lymphatic transport? Poster at 5. EACPT Congress, Odense, Denmark.
8. Gramatte T., Oertel R., Terhaag B., and Kirch W. Direct demonstration of small intestinal secretion and site-dependent absorption of the beta-blocker talinolol in humans. Clin. Pharmacol. Ther. 59 (1996) 541-549
9. Hammarlund M.M., Paalzow L.K., and Odlind B. Pharmacokinetics of furosemide in man after intravenous and oral administration. Application of moment analysis. Eur. J. Clin. Pharmacol. 26 (1984) 197-207
10. Langguth P., Lee K.M., Spahn-Langguth H., and Amidon G.L. Variable gastric emptying and discontinuities in drug absorption profiles: dependence of rates and extent of cimetidine absorption on motility phase and pH. Biopharm. Drug. Dispos. 15 (1994) 719-746
11. Lennernas H., and Regardh C.G. Evidence for an interaction between the beta-blocker pafenolol and bile salts in the intestinal lumen of the rat leading to dose-dependent oral absorption and double peaks in the plasma concentration-time profile. Pharm. Res. 10 (1993) 879-883
12. Lindell M., Karlsson M.O., Lennernas H., Pahlman L., and Lang M.A. Variable expression of CYP and Pgp genes in the human small intestine. Eur. J. Clin. Invest. 33 (2003) 493-499
13. Ludden T.M., Beal S.L., and Sheiner L.B. Comparison of the Akaike information criterion, the Schwarz criterion and the F test as guides to model selection. J. Pharmacokinet. Biopharm. 22 (1994) 431-445
14. Mahmood I. Pharmacokinetic analysis of the absorption characteristics of diclofenac sodium in man by use of a multi-segment absorption model. J. Pharm. Pharmacol. 48 (1996) 1260-1263
15. Matheny C.J., Lamb M.W., Brouwer K.R., and Pollack G.M. Pharmacokinetic and pharmacodynamic implications of P-glycoprotein modulation. Pharmacotherapy 21 (2001) 778-796
16. Meffin P.J., Winkle R.A., Peters F.A., and Harrison D.C. Dose-dependent acebutolol disposition after oral administration. Clin. Pharmacol. Ther. 24 (1978) 542-547
17. Mouly S., and Paine M.F. P-glycoprotein increases from proximal to distal regions of human small intestine. Pharm. Res. 20 (2003) 1595-1599
18. Oertel R., Richter K., Trausch B., and Gramatte T. A quick, simple HPLC method for determination of talinolol in serum. Pharmazie 49 (1994) 291-292
19. Schmitt J. Talinolol, ein klinisch bewahrter ß1-selektiver Betablocker-Eine Uebersicht zu pharmakokinetischen und pharmakodynamischen Eigenschaften. Perfusion 9 (1995) 291-296
20. Siegmund W., Ludwig K., Engel G., Zschiesche M., Franke G., Hoffmann A., Terhaag B., and Weitschies W. Variability of intestinal expression of P-glycoprotein in healthy volunteers as described by absorption of talinolol from four bioequivalent tablets. J. Pharm. Sci. 92 (2003) 604-610
21. Spahn-Langguth H., Baktir G., Radschuweit A., Okyar A., Terhaag B., Ader P., Hanafy A., and Langguth P. P-glycoprotein transporters and the gastrointestinal tract: evaluation of the potential in vivo relevance of in vitro data employing talinolol as model compound. Int. J. Clin. Pharmacol. Ther. 36 (1998) 16-24
22. Suttle A.B., and Brouwer K.L. Bile flow but not enterohepatic recirculation influences the pharmacokinetics of ranitidine in the rat. Drug. Metab. Dispos. 22 (1994) 224-232
23. Tannergren C., Langguth P., and Hoffmann K.J. Compound mixtures in caco-2 cell permeability screens as a means to increase screening capacity. Pharmazie 56 (2001) 337-342
24. Terhaag B., Gramatte T., Richter K., Voss J., and Feller K. The biliary elimination of the selective beta-receptor blocking drug talinolol in man. Int. J. Clin. Pharmacol. Ther. Toxicol. 27 (1989) 170-172
25. Wagner D., Glube N., Berntsen N., Tremel W., and Langguth P. Different dissolution media lead to different crystal structures of talinolol with impact on its dissolution and solubility. Drug. Dev. Ind. Pharm. 29 (2003) 891-902
26. Wagner D., Spahn-Langguth H., Hanafy A., Koggel A., and Langguth P. Intestinal drug efflux: formulation and food effects. Adv. Drug Deliv. Rev. 50 Suppl. 1 (2001) S13-S31
27. Walkenstein S.S., Dubb J.W., Randolph W.C., Westlake W.J., Stote R.M., and Intoccia A.P. Bioavailability of cimetidine in man. Gastroenterology 74 (1978) 360-365
28. Wang E., Casciano C.N., Clement R.P., and Johnson W.W. Cholesterol interaction with the daunorubicin binding site of P-glycoprotein. Biochem. Biophys. Res. Commun. 276 (2000) 909-9016
29. Weitschies W., Bernsdorf A., Giessmann T., Zschiesche M., Modess C., Hartmann V., Mrazek C., Wegner D., Nagel S., and Siegmund W. The talinolol double-peak phenomenon is likely caused by presystemic processing after uptake from gut lumen. Pharm. Res. 22 (2005) 728-735
30. Westphal K., Weinbrenner A., Giessmann T., Stuhr M., Franke G., Zschiesche M., Oertel R., Terhaag B., Kroemer H.K., and Siegmund W. Oral bioavailability of digoxin is enhanced by talinolol: evidence for involvement of intestinal P-glycoprotein. Clin. Pharmacol. Ther. 68 (2000) 6-12
31. Wetterich, U., 1995. Doctoral Thesis.
32. Wetterich U., Spahn-Langguth H., Mutschler E., Terhaag B., Rosch W., and Langguth P. Evidence for intestinal secretion as an additional clearance pathway of talinolol enantiomers: concentration-and dose-dependent absorption in vitro and in vivo. Pharm. Res. 13 (1996) 514-522
33. Wu C.Y., and Benet L.Z. Predicting drug disposition via application of BCS: transport/absorption/elimination interplay and development of a biopharmaceutics drug disposition classification system. Pharm. Res. 22 (2005) 11-23
34. Zhou H. Pharmacokinetic strategies in deciphering atypical drug absorption profiles. J. Clin. Pharmacol. 43 (2003) 211-227